Jian-Ming Huang

Jian-Ming Huang

Auto-generated profile, based on publicly available information

Jian-Ming Huang

School of Medicine, College of Life Sciences and Medicine, National Tsing Hua University, Hsinchu, Taiwan; Department of Medical Science, College of Life Sciences and Medicine, National Tsing Hua University, Hsinchu, Taiwan; Institute of Molecular and Cellular Biology, College of Life Sciences and Medicine, National Tsing Hua University, Hsinchu, Taiwan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DYDahong Yao
Dahong Yao
ARA. Ruhan
A. Ruhan
JJJin Jiang
Jin Jiang
JHJian Huang
Jian Huang
JWJinhui Wang
Jinhui Wang
WHWeina Han
Weina Han

21 February 2025 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
CCChun Hsien Chen
Chun Hsien Chen
JHJian-Ming Huang
Jian-Ming Huang
YWYu-Jen Wang
Yu-Jen Wang
CTChih-Ming Tsai
Chih-Ming Tsai
WLWei-Chen Lin
Wei-Chen Lin
This review examines the advancements in antimicrobial drug discovery with in vitro assays for Acanthamoeba, highlighting the efficacy of current topical antimicrobial agents. In recent decades, the treatment and diagnosis of Acanthamoeba keratitis (AK) have presented clinical challenges. Clinicians often rely on clinical judgment, risk factors, and patient travel history to guide initial treatment decisions. The clinical presentation of AK frequently coincides with bacterial and fungal keratitis, leading to delays in diagnostic confirmation. This review compiles a list of commonly used antimicrobial agents that may be useful in controlling and preventing Acanthamoeba and other microbial infections during the diagnostic waiting period. Due to their unique life cycle, consisting of both trophozoite and cyst stages, amoebae exhibit resistance to various clinical drugs. Current research efforts are focused on identifying alternative and effective treatment options. Despite the ongoing characterization of various cytocidal agents from natural and synthetic sources, chlorhexidine gluconate (CHG) and polyhexamethylene biguanide (PHMB) have emerged as the most effective therapies for AK. Drawing from previous studies, we catalog several commonly used antimicrobial agents that may enhance the efficacy of PHMB and CHG while also preventing other microbial infections. These alternative agents present promising options for treating AK cases. This review evaluates progress in anti-amoebic drug discovery, focusing on antibiotics and cataloging their activity at different stages of Acanthamoeba.

6 June 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
MSMing-Der Shi
Ming-Der Shi
KSKo-Chiang Sung
Ko-Chiang Sung
JHJian-Ming Huang
Jian-Ming Huang
CCChun Hsien Chen
Chun Hsien Chen
YWYu-Jen Wang
Yu-Jen Wang
Acanthamoeba, a widely distributed free-living amoeba found in various environments, is an opportunistic pathogen responsible for causing Acanthamoeba keratitis, a condition that may lead to blindness. However, identifying the pathogenicity of Acanthamoeba is challenging due to its complex life cycle, ability to adapt to different environments, variable virulence factors, and intricate interactions with the host immune system. Additionally, the development of an effective model for studying Acanthamoeba pathogenicity is limited, hindering a comprehensive understanding of the mechanisms underlying its virulence and host interactions. The aim of this study was to develop an ex vivo model for Acanthamoeba infection using porcine eyeballs and to evaluate the pathogenicity of the Acanthamoeba isolates. Based on slit lamp and biopsy analysis, the developed ex vivo model is capable of successfully infecting Acanthamoeba within 3 days. Histopathological staining revealed that clinical isolates of Acanthamoeba exhibited greater corneal stroma destruction and invasion in this model than environmental isolates. Our results highlight the importance of an ex vivo porcine eye model in elucidating the pathogenesis of Acanthamoeba infection and its potential implications for understanding and managing Acanthamoeba-related ocular diseases.

20 December 2008 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
BSBohang Sun
Bohang Sun
BHBailing Hou
Bailing Hou
JHJian Huang
Jian Huang
LWLijun Wu
Lijun Wu
MKMasonori Kuroyanagi
Masonori Kuroyanagi
HGHuiYuan Gao
HuiYuan Gao

22 May 2024 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
KSKuang-Yi Shih
Kuang-Yi Shih
YCYao-Tsung Chang
Yao-Tsung Chang
YWYu-Jen Wang
Yu-Jen Wang
JHJian-Ming Huang
Jian-Ming Huang
Acanthamoeba, a free-living amoeba, is commonly found in various natural environments, such as rivers and soil, as well as in public baths, swimming pools, and sewers. Acanthamoeba can cause severe illness such as granulomatous amoebic encephalitis and Acanthamoeba keratitis (AK) in humans. AK, the most recognized disease, can cause permanent visual impairment or blindness by affecting the cornea. AK commonly affects contact lens wearers who neglect proper cleaning habits. The symptoms of AK include epithelial and stromal destruction, corneal infiltrate, and intense ocular pain, occasionally necessitating surgical removal of the entire eyeball. Current AK treatment involves the hourly application of eye drops containing polyhexamethylene biocide (PHMB). However, studies have revealed their ineffectiveness against drug-resistant strains. Acanthamoeba can form cysts as a survival mechanism in adverse environments, though the exact mechanism remains unknown. Our experiments revealed that sodium P-type ATPase (ACA1_065450) is closely linked to encystation. In addition, various encystation buffers, such as MgCl2 or NaCl, induced the expression of P-type ATPase. Furthermore, we used ouabain, an ATPase inhibitor, to inhibit the Na+/K+ ion pump, consequently decreasing the encystation rate of Acanthamoeba. Our primary objective is to develop an advanced treatment for AK. We anticipate that the combination of ouabain and PHMB may serve as an effective therapeutic approach against AK in the future.

8 June 2023 in Oral Diseases
Verified
Journal Article
Closed access
YCYu Chun Chen
Yu Chun Chen
JHJian Ming Huang
Jian Ming Huang
YCYing‐Ying Chang
Ying‐Ying Chang
KYKuo Yuan
Kuo Yuan
WLWei-Chen Lin
Wei-Chen Lin
CTChun-Chan Ting
Chun-Chan Ting